GC
HRTX icon

Guggenheim Capital’s Heron Therapeutics HRTX Stock Holding History

Guggenheim Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,123
Closed -$67.8K – 1959
2022
Q4 		$67.8K Sell
27,123
-5,260
-16% -$16.9K ﹤0.01% 1888
2022
Q3 		$137K Sell
32,383
-28,587
-47% -$112K ﹤0.01% 1826
2022
Q2 		$170K Sell
60,970
-4,918
-7% -$19.7K ﹤0.01% 1967
2022
Q1 		$376K Buy
65,888
+663
+1% +$4.85K ﹤0.01% 1787
2021
Q4 		$596K Buy
65,225
+453
+0.7% +$4.63K ﹤0.01% 1604
2021
Q3 		$692K Sell
64,772
-182
-0.3% -$2.22K ﹤0.01% 1610
2021
Q2 		$1.01M Buy
64,954
+6,539
+11% +$104K 0.01% 1488
2021
Q1 		$947K Buy
58,415
+24,677
+73% +$440K 0.01% 1429
2020
Q4 		$714K Buy
33,738
+12,174
+56% +$212K ﹤0.01% 1491
2020
Q3 		$320K Buy
+21,564
New +$336K ﹤0.01% 1612
2019
Q4 		– Sell
-94,895
Closed -$1.75M – 2105
2019
Q3 		$1.75M Sell
94,895
-14,556
-13% -$268K 0.01% 1070
2019
Q2 		$2.03M Sell
109,451
-3,665
-3% -$73.2K 0.02% 1041
2019
Q1 		$2.76M Buy
113,116
+11,722
+12% +$307K 0.02% 930
2018
Q4 		$2.63M Buy
101,394
+95,058
+1,500% +$2.61M 0.02% 906
2018
Q3 		$201K Buy
+6,336
New +$236K ﹤0.01% 2333
2017
Q4 		– Sell
-143,840
Closed -$2.32M – 2756
2017
Q3 		$2.32M Buy
143,840
+26,657
+23% +$418K 0.01% 1557
2017
Q2 		$1.62M Buy
117,183
+5,075
+5% +$73.5K ﹤0.01% 1773
2017
Q1 		$1.68M Buy
112,108
+10,039
+10% +$139K ﹤0.01% 1784
2016
Q4 		$1.34M Buy
102,069
+9,339
+10% +$147K ﹤0.01% 1972
2016
Q3 		$1.6M Sell
92,730
-5,652
-6% -$105K 0.01% 1769
2016
Q2 		$1.78M Sell
98,382
-6,235
-6% -$122K 0.01% 1637
2016
Q1 		$1.99M Buy
104,617
+20,397
+24% +$402K 0.01% 1575
2015
Q4 		$2.25M Buy
84,220
+35,848
+74% +$959K 0.01% 1529
2015
Q3 		$1.18M Buy
+48,372
New +$1.61M ﹤0.01% 1992

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Guggenheim Capital's HRTX Position: Q1 2023 in Review

Guggenheim Capital sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 27,123 shares — an estimated $67.8K sold.

Guggenheim Capital first reported a position in HRTX in Q3 2015 and held it in 24 quarters. The position peaked at $2.76M in Q1 2019. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

  • Guggenheim Capital reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Guggenheim Capital sold 27,123 Heron Therapeutics shares in Q1 2023, an estimated $67.8K.
  • Guggenheim Capital first reported a position in Heron Therapeutics in Q3 2015 and held it in 24 quarters.
  • Guggenheim Capital's Heron Therapeutics position peaked at $2.76M in Q1 2019.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on Guggenheim Capital's 13F filing for Q1 2023, filed 11 May 2023.